2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4ab,The study included 4438 unique patients with psoriasis (2717 [61.2%] male; mean [SD] age, 45.0 [14.6] years at the time of their first treatment included in the study), 1039 (23.4%) of whom had comorbid psoriatic arthritis. A total of 3790 treatment series from bionaive patients were analyzed: 2646 were with adalimumab, 377 with secukinumab, and 767 with ustekinumab. The 5-year standardized risk of discontinuing ustekinumab was 0.37 (95% CI, 0.33-0.41), which was significantly lower than the standardized risks for adalimumab (0.51; 95% CI, 0.49-0.54) and secukinumab (0.54; 95% CI, 0.48-0.60). A total of 3403 treatment series from bioexperienced patients were analyzed: 790 were with adalimumab, 376 with bimekizumab, 192 with brodalumab, 218 with guselkumab, 556 with ixekizumab, 78 with risankizumab, 466 with secukinumab, and 727 with ustekinumab. The 2-year standardized absolute risk of discontinuing ustekinumab was 0.39 (95% CI, 0.36-0.43). Only bimekizumab (0.27; 95% CI, 0.20-0.34), guselkumab (0.29; 95% CI, 0.22-0.36), and risankizumab (0.25; 95% CI, 0.15-0.36) were associated with a significantly lower standardized absolute risk of discontinuation compared with ustekinumab.31:Taf0,Drug survival is an important measure to help guide treatment selection. However, clinical evidence for newer biologics, including bimekizumab, is limited. To determine the drug survival of biologics used for treating psoriasis in a routine clinical practice setting. This cohort study was based on data from the DERMBIO registry, which includes all patients treated with biologics for psoriasis in Denmark. All adult patients enrolled in DERMBIO from its inception in May 2007 until June 2025 were assessed for eligibility. Data were extracted in June 2025 and analyzed separately among those without previous biologic exposure (bionaive patients) and those with previous biologic exposure (bioexperienced patients). Adalimumab, secukinumab, and ustekinumab among bionaive patients and adalimumab, bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab among bioexperienced patients. The main outcome was standardized absolute risks of treatment discontinuation at 1, 2, and 5 years. Kaplan-Meier estimator was used to determine crude drug survival estimates and the Aalen-Johansen estimator was used to determine crude cause-specific absolute risks. The study included 4438 unique patients with psoriasis (2717 [61.2%] male; mean [SD] age, 45.0 [14.6] years at the time of their first treatment included in the study), 1039 (23.4%) of whom had comorbid psoriatic arthritis. A total of 3790 treatment series from bionaive patients were analyzed: 2646 were with adalimumab, 377 with secukinumab, and 767 with ustekinumab. The 5-year standardized risk of discontinuing ustekinumab was 0.37 (95% CI, 0.33-0.41), which was significantly lower than the standardized risks for adalimumab (0.51; 95% CI, 0.49-0.54) and secukinumab (0.54; 95% CI, 0.48-0.60). A total of 3403 treatment series from bioexperienced patients were analyzed: 790 were with adalimumab, 376 with bimekizumab, 192 with brodalumab, 218 with guselkumab, 556 with ixekizumab, 78 with risankizumab, 466 with secukinumab, and 727 with ustekinumab. The 2-year standardized absolute risk of discontinuing ustekinumab was 0.39 (95% CI, 0.36-0.43). Only bimekizumab (0.27; 95% CI, 0.20-0.34), guselkumab (0.29; 95% CI, 0.22-0.36), and risankizumab (0.25; 95% CI, 0.15-0.36) were associated with a significantly lower standardized absolute risk of discontinuation compared with ustekinumab. In this cohort study in Denmark, among bionaive patients with psoriasis, ustekinumab had superior drug survival compared with adalimumab and secukinumab, and among bioexperienced patients with psoriasis, bimekizumab, guselkumab, and risankizumab had superior drug survival. These results offer insight into the performance of different biologics in the treatment of psoriasis in a routine clinical practice setting.32:Tfc4, Importance Drug survival is an important measure to help guide treatment selection. However, clinical evidence for newer biologics, including bimekizumab, is limited. Objective To determine the drug survival of biologics used for treating psoriasis in a routine clinical practice setting. Design, Setting, and Participants This cohort study was based on data from the DERMBIO registry, which includes all patients treated with biologics for psoriasis in Denmark. All adult patients enrolled in DERMBIO from its inception in May 2007 until June 2025 were assessed for eligibility. Data were extracted in June 2025 and analyzed separately among those without previous biologic exposure (bionaive patients) and those with previous biologic exposure (bioexperienced patients). Exposures Adalimumab, secukinumab, and ustekinumab among bionaive patients and adalimumab, bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab among bioexperienced patients. Main Outcomes and Measures The main outcome was standardized absolute risks of treatment discontinuation at 1, 2, and 5 years. Kaplan-Meier estimator was used to determine crude drug survival estimates and the Aalen-Johansen estimator was used to determine crude cause-specific absolute risks. Results The study included 4438 unique patients with psoriasis (2717 [61.2%] male; mean [SD] age, 45.0 [14.6] years at the time of their first treatment included in the study), 1039 (23.4%) of whom had comorbid psoriatic arthritis. A total of 3790 treatment series from bionaive patients were analyzed: 2646 were with adalimumab, 377 with secukinumab, and 767 with ustekinumab. The 5-year standardized risk of discontinuing ustekinumab was 0.37 (95% CI, 0.33-0.41), which was significantly lower than the standardized risks for adalimumab (0.51; 95% CI, 0.49-0.54) and secukinumab (0.54; 95% CI, 0.48-0.60). A total of 3403 treatment series from bioexperienced patients were analyzed: 790 were with adalimumab, 376 with bimekizumab, 192 with brodalumab, 218 with guselkumab, 556 with ixekizumab, 78 with risankizumab, 466 with secukinumab, and 727 with ustekinumab. The 2-year standardized absolute risk of discontinuing ustekinumab was 0.39 (95% CI, 0.36-0.43). Only bimekizumab (0.27; 95% CI, 0.20-0.34), guselkumab (0.29; 95% CI, 0.22-0.36), and risankizumab (0.25; 95% CI, 0.15-0.36) were associated with a significantly lower standardized absolute risk of discontinuation compared with ustekinumab. Conclusions and Relevance In this cohort study in Denmark, among bionaive patients with psoriasis, ustekinumab had superior drug survival compared with adalimumab and secukinumab, and among bioexperienced patients with psoriasis, bimekizumab, guselkumab, and risankizumab had superior drug survival. These results offer insight into the performance of different biologics in the treatment of psoriasis in a routine clinical practice setting. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"bimekizumab: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on bimekizumab (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/bimekizumab\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"bimekizumab\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/bimekizumab\"}]}}"}}]],["$","$L2f",null,{"title":"bimekizumab: Research & Clinical Takeaways","description":"Explore research on bimekizumab (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.2340/actadv.v106.adv-2026-0797","pmid":"42708646","title":"Current Evidence on IL-17 and IL-(12)/23 Inhibitor Safety during Pregnancy in Psoriasis: A Call for Harmonized Data Collection","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-09-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0797","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-12T06:20:17.230Z","updated_at":"2026-09-12T06:20:17.230Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Bimzelx","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Siliq","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Tremfya","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"brodalumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"sample_size","value":"n=5962","value_numeric":5962},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"Level of evidence assigned as 3 (systematic review of heterogeneous, mostly observational studies); no meta-analysis was conducted due to methodological heterogeneity.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"Sex tag set to 'female' as the primary dataset covers maternal exposure; paternal exposure studies also exist but are a small subset (3 studies, 281 pregnancies).","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"The review included all indications for IL inhibitors (not psoriasis-only), so findings may not be fully generalizable to psoriasis patients specifically.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"The sample size (n=5,962) reflects maternal pregnancy exposures across all included studies, not a single trial cohort; the majority originated from pharmacovigilance databases with inherent reporting bias.","value_numeric":null}],"summaries":{"what_studied":"A PRISMA-compliant systematic literature review (search date May 2026) evaluated the reproductive safety of IL-12/23, IL-17, and IL-23 inhibitors during pregnancy and with paternal exposure in patients with psoriasis, examining pregnancy and neonatal outcomes across all available study designs.","key_result":"49 publications met inclusion criteria, reporting 5,962 pregnancies with maternal exposure; ustekinumab had the most data (2,933 pregnancies), followed by secukinumab (1,877), risankizumab (589), ixekizumab (296), guselkumab (217), tildrakizumab (32), bimekizumab (11), brodalumab (6), and mirikizumab (1). Cohort-level findings were generally reassuring — no consistent signal for adverse pregnancy or neonatal outcomes — except one study reporting increased risk of small-for-gestational-age infants with ustekinumab. Paternal exposure data were very limited (3 studies, 281 pregnancies).","limitations":"- Most exposures (n=5,074) came from pharmacovigilance databases that capture only adverse events, making incidence rates incalculable and meta-analysis infeasible.\n- Critical confounders (disease activity, exposure timing, comedications) were missing or unreported in the majority of studies; only one study used confounder-adjusted analysis.\n- Data were heavily skewed toward IBD patients, limiting psoriasis-specific and IL-17-specific conclusions.","practice_takeaway":"Available data are broadly reassuring but insufficient to issue definitive safety guidance; clinicians should weigh uncontrolled disease risk against medication uncertainty on a case-by-case basis. Existing psoriasis registries (e.g., BADBIR, BioCAPTURE) should add standardized pregnancy datasets to accelerate evidence generation."}},{"doi":"10.1001/jamadermatol.2026.2633","pmid":"42555037","title":"Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-08-05T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13445090/","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-12T13:26:05.687Z","updated_at":"2026-08-12T13:26:05.687Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"brand","value":"Bimzelx","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"modality","value":"IL-17A/F Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"modality","value":"Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"modality","value":"TNF-alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"sample_size","value":"n=6","value_numeric":6},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"study_design","value":"Economic Evaluation","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Bimekizumab brand name 'Bimzelx' assumed based on known regulatory approval; not explicitly stated in the source text.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Full text was inaccessible; summary is based solely on the abstract and results excerpt. Methodological nuances (e.g., discounting, time horizon, sensitivity analyses beyond severity adjustment) could not be verified.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Level of evidence assigned as 4 (economic/decision analysis); no direct clinical trial was conducted in this study.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Sample size tag reflects 6 Phase 3 trials used for efficacy data synthesis, not a patient-level N — no total patient count was reported in the available abstract.","value_numeric":null}],"summaries":{"what_studied":"This economic evaluation compared the cost-efficiency of three approved monoclonal antibody therapies for moderate-to-severe hidradenitis suppurativa (HS) — adalimumab, secukinumab, and bimekizumab — across five countries (US, Canada, France, Germany, Australia) using Phase 3 trial efficacy data and publicly available drug pricing as of January 31, 2026.","key_result":"Adalimumab 40 mg weekly was on the efficiency frontier in all five countries for both HiSCR-50 and HiSCR-75 outcomes. Secukinumab 300 mg every 4 weeks reached the frontier only when US wholesale acquisition costs were used. Annual costs ranged from $11,345 (adalimumab in Australia) to $411,990 (bimekizumab in the US).","limitations":"- Only publicly available list prices were used; negotiated or rebated prices, which vary widely, were not included.\n- Efficacy data were drawn from separate Phase 3 trials without head-to-head comparisons, limiting direct cross-drug efficacy inference.\n- Full-text access was unavailable; some methodological details may be incomplete.","practice_takeaway":"Adalimumab remains the most cost-efficient approved biologic for HS across major health systems, with costs up to 36-fold lower than bimekizumab in the US. Clinicians and payers advocating for value-based formulary decisions should weigh these large pricing differentials alongside efficacy data."}},{"doi":"10.1136/rmdopen-2025-006577","pmid":"42457215","title":"Psoriatic arthritis and obesity: a review of clinical burden and considerations for comprehensive care","journal_title":"RMD Open","journal_issn":"2056-5933","published_at":"2026-07-15T00:00:00.000Z","url":"https://doi.org/10.1136/rmdopen-2025-006577","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-20T13:36:05.406Z","updated_at":"2026-07-20T13:36:05.406Z","tags":[{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"brand","value":"Mounjaro","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"brand","value":"Ozempic","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"brand","value":"Wegovy","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"brand","value":"Zepbound","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"condition","value":"Metabolic Syndrome","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"generic","value":"semaglutide","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"generic","value":"tirzepatide","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"modality","value":"GIP/GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"modality","value":"GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"sample_size","value":"n=49","value_numeric":49},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"warning","value":"Sample size tag reflects the number of included studies in the narrative review, not a patient-level N.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the TOGETHER-PsA combination therapy signal and the emerging incretin data; clinicians should note that PsA-specific regulatory approvals for GLP-1/GIP RAs are not yet established.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"warning","value":"The TOGETHER-PsA trial (n=271) results cited are from a 2026 publication; full peer-reviewed data should be independently verified as the review appears to have had early access.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006577","tag_type":"warning","value":"This review was funded by Eli Lilly and Company, and three co-authors are Lilly employees; tirzepatide (a Lilly product) is featured prominently including data from the TOGETHER-PsA trial authored by overlapping investigators.","value_numeric":null}],"summaries":{"what_studied":"This narrative review examined the interplay between psoriatic arthritis (PsA) and obesity, covering shared inflammatory pathways, impact on disease severity and treatment response, weight-management strategies (lifestyle, bariatric surgery, pharmacological), and the potential role of incretin-based therapies (GLP-1 RAs, dual GIP/GLP-1 RAs). Literature search covered PubMed, Embase, and Scopus up to October 2025; 49 studies were included.","key_result":"Obesity (BMI ≥30) worsens PsA severity, reduces biologic response, and raises cardiovascular risk. Key data points: each 1-unit BMI rise in psoriasis patients increases PsA risk by 5.3%; modest weight loss (5–10% body weight) improves disease activity; in one trial, ACR20 response was 71% vs 30% (p=0.008) in patients who lost ≥18.6% weight. The TOGETHER-PsA trial (n=271) found ixekizumab plus tirzepatide achieved ACR50 and ≥10% weight loss at week 36 in 31.7% vs 0.8% with ixekizumab alone (p<0.001), with higher ACR50 rates (33.5% vs 20.4%; p=0.02).","limitations":"- Non-systematic search introduces selection bias despite efforts to prioritize higher-quality evidence.\n- Three authors are Eli Lilly employees and the study was funded by Eli Lilly, raising potential conflict of interest given tirzepatide (Mounjaro/Zepbound) is a Lilly product prominently featured.\n- PsA-specific outcome data for incretin-based therapies remain limited; most cardiovascular and weight-loss data derive from diabetes or general obesity populations.","practice_takeaway":"Treat obesity as a core comorbidity in PsA—screen BMI routinely, integrate weight-management counseling into every rheumatology visit, and consider GLP-1 RA or GIP/GLP-1 RA co-therapy for patients with PsA and obesity who have inadequate response to biologics alone. Multidisciplinary coordination with endocrinology, dietetics, and primary care is recommended by EULAR, GRAPPA, and ACR/NPF guidelines."}},{"doi":"10.1001/jamadermatol.2025.5205","pmid":"41499137","title":"Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-01-07T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12780981/","source_score":26,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-10","doi":"10.1001/jamadermatol.2025.5205","days":"14","issn":"2168-6068","rank":"2","field":"Clinical Medicine","score":"26","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.5205","title":"Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"41499137","conclusions":"","publication_date":"2026-01-07T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.5205","URL":"https://doi.org/10.1001/jamadermatol.2025.5205","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2843485/jamadermatology_schwarz_2026_oi_250064_1766518249.66247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis"],"author":[{"given":"Christopher Willy","family":"Schwarz","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}]},{"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, Denmark"}]},{"given":"Lars Erik","family":"Bryld","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital, Roskilde, Denmark"}]},{"given":"Christoffer Valdemar","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Dermatology, Copenhagen University Hospital–Bispebjerg, Copenhagen, Denmark"}]},{"given":"Kawa Khaled","family":"Ajgeiy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Odense University Hospital, Odense, Denmark"}]},{"given":"Trine","family":"Bertelsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Kasper Fjellhaugen","family":"Hjuler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark"}]},{"given":"Tomas Norman","family":"Dam","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Nykoebing Falster, Denmark"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Mads Kirchheiner","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}]}],"issued":{"date-parts":[[2026,1,7]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T16:31:10Z","timestamp":1767803470000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-07T18:54:29Z","timestamp":1767812069040,"date-parts":[[2026,1,7]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2843485"}},"subtitle":[],"deposited":{"date-time":"2026-01-07T16:31:11Z","timestamp":1767803471000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2026,1,7]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1002/14651858.CD011535.pub6","key":"doi250064r1","year":"2023","issue":"7","author":"Sbidian","volume":"7","first-page":null,"unstructured":null,"article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2022.2909","key":"doi250064r2","year":"2022","issue":"10","author":"Yiu","volume":"158","first-page":"1131","unstructured":null,"article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-022-00722-y","key":"doi250064r3","year":"2022","issue":"6","author":"Torres","volume":"23","first-page":"891","unstructured":null,"article-title":"Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study.","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad035","key":"doi250064r4","year":"2023","issue":"6","author":"Strober","volume":"188","first-page":"749","unstructured":null,"article-title":"Bimekizumab maintenance of response through 3?years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2018.0183","key":"doi250064r5","year":"2018","issue":"5","author":"Mason","volume":"154","first-page":"581","unstructured":null,"article-title":"Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1177/24755303241234292","key":"doi250064r6","year":"2024","issue":"2","author":"Schwarz","volume":"9","first-page":"51","unstructured":null,"article-title":"Characteristics of patients with psoriasis treated with various biologics - a Danish cohort study.","journal-title":"J Psoriasis Psoriatic Arthritis","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2021.0221","key":"doi250064r7","year":"2021","issue":"6","author":"Loft","volume":"157","first-page":"676","unstructured":null,"article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(07)61602-X","key":"doi250064r8","year":"2007","issue":"9596","author":"von Elm","volume":"370","first-page":"1453","unstructured":null,"article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.16102","key":"doi250064r9","year":"2018","issue":"2","author":"Egeberg","volume":"178","first-page":"509","unstructured":null,"article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.semarthrit.2022.151979","key":"doi250064r10","year":"2022","issue":null,"author":"Egeberg","volume":"53","first-page":null,"unstructured":null,"article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - a nationwide cohort study from the DANBIO and DERMBIO registries.","journal-title":"Semin Arthritis Rheum","doi-asserted-by":"publisher"},{"DOI":"10.1093/ije/dyr213","key":"doi250064r11","year":"2012","issue":"3","author":"Andersen","volume":"41","first-page":"861","unstructured":null,"article-title":"Competing risks in epidemiology: possibilities and pitfalls.","journal-title":"Int J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.18637/jss.v045.i03","key":"doi250064r12","year":"2011","issue":"3","author":"van Buuren","volume":"45","first-page":"1","unstructured":null,"article-title":"mice: multivariate imputation by chained equations in R.","journal-title":"J Stat Softw","doi-asserted-by":"publisher"},{"DOI":"10.2147/CLEP.S129785","key":"doi250064r13","year":"2017","issue":null,"author":"Pedersen","volume":"9","first-page":"157","unstructured":null,"article-title":"Missing data and multiple imputation in clinical epidemiological research.","journal-title":"Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2022.2082354","key":"doi250064r14","year":"2022","issue":"6","author":"Kojanova","volume":"33","first-page":"2827","unstructured":null,"article-title":"Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.15251","key":"doi250064r15","year":"2024","issue":"1","author":"Mastorino","volume":"22","first-page":"34","unstructured":null,"article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.20739","key":"doi250064r16","year":"2025","issue":"10","author":"Motedayen Aval","volume":"39","first-page":"1785","unstructured":null,"article-title":"Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British Association of Dermatologists Biologics and Immunomodulators Register cohort study.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2024.05.085","key":"doi250064r17","year":"2024","issue":"5","author":"Sood","volume":"91","first-page":"936","unstructured":null,"article-title":"Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 52-week multicenter retrospective study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2025.04.038","key":"doi250064r18","year":"2025","issue":"3","author":"Blauvelt","volume":"93","first-page":"644","unstructured":null,"article-title":"Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2102383","key":"doi250064r19","year":"2021","issue":"2","author":"Reich","volume":"385","first-page":"142","unstructured":null,"article-title":"Bimekizumab versus secukinumab in plaque psoriasis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdin.2025.04.011","key":"doi250064r20","year":"2025","issue":null,"author":"Lovegrove","volume":"21","first-page":null,"unstructured":null,"article-title":"Exploring bimekizumab for psoriasis treatment: multicentre perspectives from Canada.","journal-title":"JAAD Int","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad429","key":"doi250064r21","year":"2024","issue":"4","author":"Gordon","volume":"190","first-page":"477","unstructured":null,"article-title":"Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3?years of treatment in randomized phase III trials.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ajd.14254","key":"doi250064r22","year":"2024","issue":"4","author":"Ting","volume":"65","first-page":"350","unstructured":null,"article-title":"Drug survival of biologics in psoriasis: an Australian multicentre retrospective study.","journal-title":"Australas J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19701","key":"doi250064r23","year":"2021","issue":"6","author":"Graier","volume":"184","first-page":"1094","unstructured":null,"article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.15157","key":"doi250064r24","year":"2022","issue":"7","author":"Soenen","volume":"47","first-page":"1324","unstructured":null,"article-title":"Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/jvc2.491","key":"doi250064r25","year":"2024","issue":"5","author":"Schots","volume":"3","first-page":"1499","unstructured":null,"article-title":"Ixekizumab trough concentrations in psoriasis: paving the way towards personalised therapy: a cohort study.","journal-title":"JEADV Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1002/jcph.876","key":"doi250064r26","year":"2017","issue":"7","author":"Bruin","volume":"57","first-page":"876","unstructured":null,"article-title":"Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis.","journal-title":"J Clin Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2018.04.019","key":"doi250064r27","year":"2018","issue":"10","author":"Reich","volume":"138","first-page":"2168","unstructured":null,"article-title":"Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2023.04.009","key":"doi250064r28","year":"2023","issue":"11","author":"Thein","volume":"143","first-page":"2211","unstructured":null,"article-title":"Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment - a nationwide cohort study.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.1677","key":"doi250064r29","year":"2024","issue":"8","author":"Hjort","volume":"160","first-page":"830","unstructured":null,"article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":29,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,7]]},"references-count":29,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.5205","is_oa":true,"title":"Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis","updated":"2026-01-13T16:36:47+00:00","published_date":"2026-01-07","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12780981/","pmh_id":"oai:pubmedcentral.nih.gov:12780981","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12780981/"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"brodalumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"sample_size","value":"n=4438","value_numeric":4438},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"warning","value":"Bionaive analyses included only three biologics, so results may not generalize across all classes.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"warning","value":"Different follow-up windows were used for bionaive (5-year) vs bioexperienced (2-year) estimates, limiting cross-cohort comparisons.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5205","tag_type":"warning","value":"Some agents had small sample sizes in the bioexperienced group (e.g., risankizumab n=78), increasing uncertainty.","value_numeric":null}],"summaries":{"what_studied":"A Danish registry cohort (DERMBIO) of 4438 adults with psoriasis (2007–2025) evaluated biologic drug survival using standardized absolute risks of discontinuation at 1, 2, and 5 years, analyzed separately for bionaive and bioexperienced patients.","key_result":"Bionaive: 5-year standardized discontinuation risk was 0.37 (95% CI, 0.33-0.41) for ustekinumab vs 0.51 (0.49-0.54) for adalimumab and 0.54 (0.48-0.60) for secukinumab. Bioexperienced: 2-year risk was 0.39 (0.36-0.43) for ustekinumab and lower for bimekizumab 0.27 (0.20-0.34), guselkumab 0.29 (0.22-0.36), and risankizumab 0.25 (0.15-0.36).","limitations":"Bionaive analyses included only adalimumab, secukinumab, and ustekinumab, limiting class-wide comparisons. Some bioexperienced drugs had small sample sizes (e.g., risankizumab n=78), and follow-up windows differed (5-year bionaive vs 2-year bioexperienced), complicating cross-cohort comparisons.","practice_takeaway":"In routine practice, ustekinumab showed better 5-year persistence than adalimumab and secukinumab in bionaive patients; among bioexperienced patients, bimekizumab, guselkumab, and risankizumab had lower 2-year discontinuation risks than ustekinumab. These real-world survival estimates can guide selection of biologics for psoriasis, especially after prior biologic exposure."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"bimekizumab"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"bimekizumab"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"bimekizumab"}}}]]

Papers